VAXX
Vaxxinity, Inc. Class A Common StockVAXX
VAXX
Delisted
VAXX was delisted on the 8th of May, 2024.
About: Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.
Employees: 53
Financial journalist opinion
Neutral
Finbold
11 months ago
Congress makes $4.5 trading stocks in a day; Here's the biggest winners
Though it isn't unheard of for a member of Congress to have not traded any stocks after getting elected while supporting tighter regulations for politicians' equities market activity, the House and the Senate are nonetheless seemingly filled with exceptionally savvy investors.
Neutral
GlobeNewsWire
1 year ago
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
Positive
InvestorPlace
1 year ago
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Vaxxinity (NASDAQ: VAXX ) stock is up on Friday with heavy pre-market trading of the biotechnology company's shares. That has more than 21 million shares of VAXX stock changing hands as of this writing.
Negative
InvestorPlace
1 year ago
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity (NASDAQ: VAXX ) stock is falling hard on Monday after the biotechnology company announced plans to voluntarily delist its shares from the Nasdaq Exchange. Vaxxinity will file to delist its shares on April 29, 2024.
Neutral
GlobeNewsWire
1 year ago
Vaxxinity Issues Shareholder Letter
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.
Neutral
GlobeNewsWire
1 year ago
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.
Neutral
GlobeNewsWire
1 year ago
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease
Neutral
GlobeNewsWire
1 year ago
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Neutral
GlobeNewsWire
1 year ago
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients
Neutral
GlobeNewsWire
1 year ago
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
Charts implemented using Lightweight Charts™